Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 12, 2025 | $2.20 | 2025-05-09 | 2025-05-09 |
| June 6, 2024 | $2.04 | 2024-05-09 | 2024-05-10 |
| June 23, 2023 | $1.90 | 2023-05-30 | 2023-05-31 |
| May 31, 2022 | $1.75 | 2022-05-04 | 2022-05-05 |
| May 26, 2021 | $1.93 | 2021-05-03 | 2021-05-04 |
Dividends Summary
- Sanofi American Depositary Shares (Each representing one-half of one ordinary share) has issued 18 dividend payments over the past 17 years
- The most recent dividend was paid 145 days ago, on June 12, 2025
- The highest dividend payed out to investors during this period was $2.20 per share
- The average dividend paid during this period was $1.76 per share.
Company News
The pulmonary emphysema market is projected to grow steadily by 2034, driven by increasing COPD prevalence, an aging population, and advances in therapeutic treatments. Emerging therapies and innovative drugs are expected to transform the market landscape.
Regeneron reported Q3 earnings of $11.83 per share, beating expectations, with sales of $3.75 billion. Eylea sales decreased due to competitive pressures, while Dupixent sales and Sanofi collaboration revenue showed strength.
Recursion Pharmaceuticals is an AI-powered 'TechBio' company using artificial intelligence to accelerate drug discovery and development, with promising clinical-stage programs in cancer and rare diseases, and partnerships with major pharmaceutical companies.
Regeneron Pharmaceuticals reported better-than-expected Q2 results, driven by growth in Eylea HD, Dupixent, and Libtayo. However, Eylea sales declined due to increased competition. The company's pipeline progress was mixed, with a delay in the FDA decision for linvoseltamab and a three-month extension for the Dupixent COPD indication.
JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.